Jin Woo Choi1,2, Anna Jo1,3, Min Kim1, Ho Seon Park1,4, Sung Soo Chung1, Shinae Kang5,6, Kyong Soo Park7,8. 1. Department of Internal Medicine, College of Medicine, Seoul National University, 101 Daehak-ro, Jongno-gu, Seoul, 03080, South Korea. 2. Department of Biomedical Sciences, College of Medicine, Seoul National University, Seoul, South Korea. 3. Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, South Korea. 4. Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, 211 Eonju-ro (146-92 Dogok-dong), Gangnam-gu, Seoul, 135-710, South Korea. 5. Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, 211 Eonju-ro (146-92 Dogok-dong), Gangnam-gu, Seoul, 135-710, South Korea. shinae95@yuhs.ac. 6. Severance Institute for Vascular and Metabolic Research, Yonsei University College of Medicine, Seoul, South Korea. shinae95@yuhs.ac. 7. Department of Internal Medicine, College of Medicine, Seoul National University, 101 Daehak-ro, Jongno-gu, Seoul, 03080, South Korea. kspark@snu.ac.kr. 8. Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, South Korea. kspark@snu.ac.kr.
Abstract
AIMS/HYPOTHESIS: Adipose tissue is a highly versatile system in which mitochondria in adipocytes undergo significant changes during active tissue remodelling. BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (BNIP3) is a mitochondrial protein and a known mitochondrial quality regulator. In this study, we investigated the role of BNIP3 in adipocytes, specifically under conditions of peroxisome proliferator-activated receptor-γ (PPARγ)-induced adipose tissue remodelling. METHODS: The expression of BNIP3 was evaluated in 3T3-L1 adipocytes in vitro, C57BL/6 mice fed a high-fat diet and db/db mice in vivo. Mitochondrial bioenergetics was investigated in BNIP3-knockdown adipocytes after rosiglitazone treatment. A putative peroxisome proliferator hormone responsive element (PPRE) was characterised by promoter assay and electrophoretic mobility shift assay (EMSA). RESULTS: The protein BNIP3 was more abundant in brown adipose tissue than white adipose tissue. Furthermore, BNIP3 expression was upregulated by 3T3-L1 pre-adipocyte differentiation, starvation and rosiglitazone treatment. Conversely, BNIP3 expression in adipocytes decreased under various conditions associated with insulin resistance. This downregulation of BNIP3 was restored by rosiglitazone treatment. Knockdown of BNIP3 in adipocytes inhibited rosiglitazone-induced mitochondrial biogenesis and function, partially mediated by the 5' AMP-activated protein kinase (AMPK)-peroxisome proliferator-activated receptor γ, co-activator 1 α (PGC1α) signalling pathway. Rosiglitazone treatment increased the transcription level of Bnip3 in the reporter assay and the presence of the PPRE site in the Bnip3 promoter was demonstrated by EMSA. CONCLUSIONS/ INTERPRETATION: The protein BNIP3 contributes to the improvement of mitochondrial bioenergetics that occurs on exposure to rosiglitazone. It may be a novel therapeutic target for restoring mitochondrial dysfunction under insulin-resistant conditions.
AIMS/HYPOTHESIS: Adipose tissue is a highly versatile system in which mitochondria in adipocytes undergo significant changes during active tissue remodelling. BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (BNIP3) is a mitochondrial protein and a known mitochondrial quality regulator. In this study, we investigated the role of BNIP3 in adipocytes, specifically under conditions of peroxisome proliferator-activated receptor-γ (PPARγ)-induced adipose tissue remodelling. METHODS: The expression of BNIP3 was evaluated in 3T3-L1 adipocytes in vitro, C57BL/6 mice fed a high-fat diet and db/db mice in vivo. Mitochondrial bioenergetics was investigated in BNIP3-knockdown adipocytes after rosiglitazone treatment. A putative peroxisome proliferator hormone responsive element (PPRE) was characterised by promoter assay and electrophoretic mobility shift assay (EMSA). RESULTS: The protein BNIP3 was more abundant in brown adipose tissue than white adipose tissue. Furthermore, BNIP3 expression was upregulated by 3T3-L1 pre-adipocyte differentiation, starvation and rosiglitazone treatment. Conversely, BNIP3 expression in adipocytes decreased under various conditions associated with insulin resistance. This downregulation of BNIP3 was restored by rosiglitazone treatment. Knockdown of BNIP3 in adipocytes inhibited rosiglitazone-induced mitochondrial biogenesis and function, partially mediated by the 5' AMP-activated protein kinase (AMPK)-peroxisome proliferator-activated receptor γ, co-activator 1 α (PGC1α) signalling pathway. Rosiglitazone treatment increased the transcription level of Bnip3 in the reporter assay and the presence of the PPRE site in the Bnip3 promoter was demonstrated by EMSA. CONCLUSIONS/ INTERPRETATION: The protein BNIP3 contributes to the improvement of mitochondrial bioenergetics that occurs on exposure to rosiglitazone. It may be a novel therapeutic target for restoring mitochondrial dysfunction under insulin-resistant conditions.
Authors: Saverio Cinti; Grant Mitchell; Giorgio Barbatelli; Incoronata Murano; Enzo Ceresi; Emanuela Faloia; Shupei Wang; Melanie Fortier; Andrew S Greenberg; Martin S Obin Journal: J Lipid Res Date: 2005-09-08 Impact factor: 5.922
Authors: D L Feinstein; A Spagnolo; C Akar; G Weinberg; P Murphy; V Gavrilyuk; C Dello Russo Journal: Biochem Pharmacol Date: 2005-07-15 Impact factor: 5.858
Authors: C Vande Velde; J Cizeau; D Dubik; J Alimonti; T Brown; S Israels; R Hakem; A H Greenberg Journal: Mol Cell Biol Date: 2000-08 Impact factor: 4.272
Authors: Maryam Ahmadian; Jae Myoung Suh; Nasun Hah; Christopher Liddle; Annette R Atkins; Michael Downes; Ronald M Evans Journal: Nat Med Date: 2013-05-07 Impact factor: 53.440
Authors: Shi Pan; Sushrut D Shah; Reynold A Panettieri; Deepak A Deshpande Journal: Am J Physiol Lung Cell Mol Physiol Date: 2019-09-11 Impact factor: 5.464
Authors: Nolwenn Joffin; Vivian A Paschoal; Christy M Gliniak; Clair Crewe; Abdallah Elnwasany; Luke I Szweda; Qianbin Zhang; Chelsea Hepler; Christine M Kusminski; Ruth Gordillo; Da Young Oh; Rana K Gupta; Philipp E Scherer Journal: Cell Stem Cell Date: 2021-02-03 Impact factor: 24.633
Authors: Marc J Tol; Roelof Ottenhoff; Marco van Eijk; Noam Zelcer; Jan Aten; Sander M Houten; Dirk Geerts; Cindy van Roomen; Marlou C Bierlaagh; Saskia Scheij; Marten A Hoeksema; Johannes M Aerts; Jonathan S Bogan; Gerald W Dorn; Carmen A Argmann; Arthur J Verhoeven Journal: Diabetes Date: 2016-06-20 Impact factor: 9.461
Authors: Su Myung Jung; Chien-Min Hung; Samuel R Hildebrand; Joan Sanchez-Gurmaches; Barbara Martinez-Pastor; Jivani M Gengatharan; Martina Wallace; Dimpi Mukhopadhyay; Camila Martinez Calejman; Amelia K Luciano; Wen-Yu Hsiao; Yuefeng Tang; Huawei Li; Danette L Daniels; Raul Mostoslavsky; Christian M Metallo; David A Guertin Journal: Mol Cell Date: 2019-08-22 Impact factor: 17.970
Authors: Minyoung Lee; Ho Seon Park; Min Yeong Choi; Hak Zoo Kim; Sung Jin Moon; Ji Yoon Ha; ARim Choi; Young Woo Park; Jong Suk Park; Eui-Cheol Shin; Chul Woo Ahn; Shinae Kang Journal: J Clin Med Date: 2020-05-08 Impact factor: 4.241